期刊
TRENDS IN CANCER
卷 1, 期 2, 页码 124-135出版社
CELL PRESS
DOI: 10.1016/j.trecan.2015.08.001
关键词
-
类别
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC: MFAG) [14641]
- Ministero Italiano della Salute [RF_GR-2011-02351355]
- Programma per i Giovani Ricercatori
- AIRC
- Ligue contre le Cancer
- Agence National de la Recherche (ANR) - Projets Blancs
- ANR
- ERA-Net for Research on Rare Diseases
- Association pour la Recherche sur le Cancer (ARC)
- Canceropole Ile-de-France
- Institut National du Cancer (INCa)
- Fondation Bettencourt-Schueller
- Fondation de France
- Fondation pour la Recherche Medicale (FRM)
- European Commission (ArtForce)
- European Research Council (ERC)
- LabEx Immuno-Oncology
- SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE)
- SIRIC Cancer Research and Personalized Medicine (CARPEM)
- Paris Alliance of Cancer Research Institutes (PACRI)
The propagation of whole-chromosome (aneuploid) or whole-genome (polyploid) defects is normally prevented by robust cell-intrinsic mechanisms. Moreover, non-diploid cells are under strict immunological surveillance. Nonetheless, tumors contain a high percentage of non-diploid genomes, indicating that malignant cells acquire the ability to bypass these control mechanisms and obtain a survival/proliferation benefit from bulky karyotypic defects. The non-diploid state imposes a significant metabolic burden on cancer cells and hence can be selectively targeted for therapeutic purposes. Here we discuss the impact of abnormal karyotypes on oncogenesis, tumor progression, and response to treatment, focusing on the biochemical and metabolic liabilities of non-diploid cells that can be harnessed for the development of novel chemo (immuno) therapeutic regimens against cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据